A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis

A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis

Abstract Background Interleukin-6 (IL-6) transduces signals via phosphorylation of STAT3 (pSTAT3). Tocilizumab (TCZ) is an IL-6 receptor blocker, which, when administered intravenously every 4 weeks, efficiently ameliorates rheumatoid arthritis (RA). Since IL-6 signal strength varies among patients...

Full description

Bibliographic Details
Main Authors: Shuntaro Saito, Katsuya Suzuki, Keiko Yoshimoto, Yuko Kaneko, Yoshihiro Matsumoto, Kunihiro Yamaoka, Tsutomu Takeuchi
Format: Article
Language:English
Published: BMC 2017-10-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Tocilizumab
Interleukin-6
Phosphorylated STAT3
CD4+ T cell
Online Access:http://link.springer.com/article/10.1186/s13075-017-1434-6

Internet

http://link.springer.com/article/10.1186/s13075-017-1434-6

Similar Items